Read by QxMD icon Read

Gynecologic Oncology

Eric R Craig, Angelina I Londoño, Lyse A Norian, Rebecca C Arend
OBJECTIVE: Epithelial ovarian cancer continues to be the deadliest gynecologic malignancy. Patients with both diabetes mellitus and obesity have poorer outcomes, yet research correlating metabolic abnormalities, such as metabolic syndrome, to ovarian cancer risk and outcomes is lacking. This article reviews the literature regarding metabolic derangements and their relationship to epithelial ovarian cancer, with a focus on potential mechanisms behind these associations. METHODS: PubMed and Google Scholar were searched for articles in the English language regarding epithelial ovarian cancer, obesity, diabetes mellitus, and metabolic syndrome, with a focus on studies conducted since 1990...
October 14, 2016: Gynecologic Oncology
Stella Capriglione, Francesco Plotti, Roberto Montera, Daniela Luvero, Salvatore Lopez, Giuseppe Scaletta, Alessia Aloisi, Giovan Battista Serra, Roberto Angioli
OBJECTIVES: To examine the effects of paroxetine supplementation on hot flashes and sleep in gynecological cancer survivors. METHODS: In a randomized, double-blind, placebo-controlled study, postmenopausal women with a prior history of stage 0-III gynecological cancer who had completed active cancer treatment (including hormonal therapy) were randomly assigned 1:1 to either 7.5mg oral paroxetine or placebo daily for 16weeks. Sleep and hot flashes were assessed at baseline, week 4 and week 16...
October 14, 2016: Gynecologic Oncology
Eric Leblanc, Fabrice Narducci, Lucie Bresson, Delphine Hudry
OBJECTIVE: To explore the feasibility of an oncologically acceptable management for an intermediate-risk endometrial cancer (EC) in an elderly, using the combination of transvaginal single-port laparoscopy and sentinel node policy. METHODS: For this 85-years old patient, BMI 32kg/m(2), with IB grade 2 endometrioid EC, a single vaginal approach was attempted [1] to perform a total hysterectomy, bilateral salpinago-oophorectomy and pelvic node assessment guided by SND [2]...
October 13, 2016: Gynecologic Oncology
Huimin Bai, Dongyan Cao, Fang Yuan, Guihua Sha, Jiaxin Yang, Jie Chen, Yue Wang, Zhenyu Zhang, Keng Shen
OBJECTIVES: To investigate the prognostic value of endometriosis in patients with stage I ovarian clear cell carcinoma (OCCC). METHODS: The medical records of patients with stage I OCCC who had undergone complete staging surgery followed by systemic chemotherapy were retrospectively reviewed. RESULTS: A total of 237 women were included in this study. Univariate analysis revealed that the patients with endometriosis-associated ovarian carcinoma (EAOC) had significantly improved recurrence-free survival (RFS) and overall survival (OS) than those without EAOC (5-year RFS: 91...
October 13, 2016: Gynecologic Oncology
Pamela T Soliman, Qian Zhang, Russell R Broaddus, Shannon N Westin, David Iglesias, Mark F Munsell, Rosemarie Schmandt, Melinda Yates, Lois Ramondetta, Karen H Lu
OBJECTIVE: Metformin reduces cancer incidence and improves overall survival in diabetic patients. In preclinical studies, metformin decreases endometrial cancer (EC) cell growth by activation of AMPK/mTOR inhibition. We sought to determine the effects of metformin on serum/tumor biomarkers in women with EC. METHODS: In this prospective trial, newly diagnosed EC patients underwent pre-treatment blood draw/endometrial biopsy, were administered oral metformin 850mg daily for ≥7days, and underwent post-treatment blood draw/definitive surgery...
October 13, 2016: Gynecologic Oncology
Jubilee Brown, R Wendel Naumann, Michael J Seckl, Julian Schink
Significant improvements in treatment and the understanding of gestational trophoblastic neoplasia have occurred in the last 15years. These diseases are almost always curable, and refractory patients have more options for salvage therapy. Recent improvements in the understanding of epidemiology, diagnosis, and cell biology have resulted in changes in staging, advances in treatment options, and opportunities for fertility preservation.
October 13, 2016: Gynecologic Oncology
Hee Seung Kim, Robert E Bristow, Suk-Joon Chang
OBJECTIVE: The majority of advanced ovarian cancer patients have peritoneal carcinomatosis involving from the pelvis to upper abdomen, which is a major obstacle to optimal cytoreduction. Since total parietal peritonectomy was introduced for treating peritoneal carcinomatosis from colorectal cancer [3], similar surgical techniques including pelvic peritonectomy have been applied in advanced ovarian cancer with peritoneal carcinomatosis [1], and these can increase the rate of complete cytoreduction up to 60% [2]...
October 13, 2016: Gynecologic Oncology
Amanda N Fader, James Java, Meaghan Tenney, Stephanie Ricci, Camille C Gunderson, Sarah M Temkin, Nick Spirtos, Christina L Kushnir, Michael L Pearl, Oliver Zivanovic, Krishnansu S Tewari, David O'Malley, Ellen M Hartenbach, Chad A Hamilton, Natalie S Gould, Robert S Mannel, William Rodgers, Joan L Walker
OBJECTIVES: We sought to analyze the clinicopathologic features, recurrence patterns and survival outcomes of women with high-grade uterine cancer (UC) enrolled on The Gynecologic Oncology Group (GOG) LAP2 trial. METHODS: This is a post-hoc analysis of LAP-2 patients with grade 3 endometrioid adenocarcinoma (ENDO), uterine serous (USC), clear cell (CC) and carcinosarcoma (CS). Demographics, clinicopathologic features, and recurrence patterns, were compared by histology and surgical approach...
October 12, 2016: Gynecologic Oncology
N D Fleming, P T Ramirez, P T Soliman, K M Schmeler, G B Chisholm, A M Nick, S N Westin, M Frumovitz
OBJECTIVES: To longitudinally assess quality of life (QOL) in women undergoing radical trachelectomy for early-stage cervical cancer. METHODS: We prospectively enrolled patients with stage IA1-IB1 cervical cancer prior to undergoing radical trachelectomy to complete validated QOL instruments. These instruments included the General Health-Related QOL (SF-12), Functional Assessment of Cancer Therapy-Cervix (FACT-Cx), MD Anderson Symptom Inventory (MDASI), Female Sexual Functioning Index (FSFI), and Satisfaction with Decision scale (SWD)...
October 11, 2016: Gynecologic Oncology
Genevieve K Lennox, Allan Covens
OBJECTIVE: Evaluate recurrence-free survival (RFS) and short-term morbidity in patients with early cervical cancer who undergo bilateral pelvic lymphadenectomy (BPLND) versus bilateral sentinel lymph node biopsy only (BSLNB) at primary surgery. METHODS: All patients with pathologically confirmed node negative stage IA/IB cervical cancer managed with BPLND or BSLNB were identified in the University of Toronto's prospective cervical cancer database from May 1984-June 2015...
October 11, 2016: Gynecologic Oncology
Saara Bryk, Anniina Färkkilä, Ralf Bützow, Arto Leminen, Johanna Tapper, Markku Heikinheimo, Leila Unkila-Kallio, Annika Riska
OBJECTIVE: Adult-type ovarian granulosa cell tumors (AGCTs) have an unpredictable tendency to relapse. In a carefully validated patient cohort, we evaluated the prognostic factors related to AGCT recurrence. METHODS: We identified all patients diagnosed with AGCT during 1956-2014 in Helsinki University Hospital, with a minimum follow-up of one year (n=240). After a histological review supplemented with FOXL2 (402C-G) mutation status analysis, we analyzed the clinical data for association with relapse...
October 8, 2016: Gynecologic Oncology
Arlene E Garcia-Soto, James J Java, Wilberto Nieves Neira, J Matthew Pearson, David E Cohn, Shashikant B Lele, Krishnansu S Tewari, Joan L Walker, Angeles Alvarez Secord, Deborah K Armstrong, Larry J Copeland
OBJECTIVES: To determine the relationship of the time from surgery to intraperitoneal (IP) chemotherapy (TSIC) initiation with survival of patients with stage III epithelial ovarian cancer (EOC) patients using ancillary data from cooperative group clinical trials. METHODS: Data from 420 patients with stage III EOC treated with IP chemotherapy under GOG-0114 and 172 were reviewed. The Cox proportional hazards model was used to evaluate independent prognostic factors and estimate their covariate-adjusted effects on PFS and OS...
October 7, 2016: Gynecologic Oncology
Yanbin Liao, Yalan Deng, Jun Liu, Zhanying Ye, Zeshan You, Shuzhong Yao, Shanyang He
OBJECTIVE: Ovarian cancer is one of the most lethal gynecologic malignancies worldwide and with poor prognosis and survival rate in women. Identifying sensitive and specific molecular in carcinogenesis may improve diagnostic and therapeutic strategies for this malignancy and achieve a better clinical outcome. METHODS: miR-760 expression in ovarian cancer cell lines and patient tissues were determined using Real-time PCR. 145 human ovarian cancer tissue samples were analyzed by RT-PCR to investigate the association between miR-760expression and the clinicopathological characteristics of ovarian cancer patients...
October 7, 2016: Gynecologic Oncology
Dustin Boothe, Andrew Orton, Bismarck Odei, Gregory Stoddard, Gita Suneja, Matthew M Poppe, Theresa L Werner, David K Gaffney
No abstract text is available yet for this article.
October 7, 2016: Gynecologic Oncology
Linda P Cho, Matthias Manuel, Paul Catalano, Larissa Lee, Antonio L Damato, Robert A Cormack, Ivan Buzurovic, Mandar Bhagwat, Desmond O'Farrell, Phillip M Devlin, Akila N Viswanathan
OBJECTIVE: To determine prognostic factors for progression-free survival (PFS) and overall survival (OS) for stage I-II cervical-cancer patients treated using computed-tomography (CT)-planned high-dose-rate (HDR) intracavitary brachytherapy (BT). METHODS: A total of 150 patients were treated for Stage I-II cervical cancer using CT-planned BT between 4/2004 and 10/2014. Of these, 128 were eligible for inclusion. Kaplan-Meier local control (LC), pelvic control (PC), overall survival (OS), and PFS estimates were calculated...
October 6, 2016: Gynecologic Oncology
David A Barrington, Sarah E Dilley, Emily E Landers, Eric D Thomas, Jonathon D Boone, J Michael Straughn, Gerald McGwin, Charles A Leath
OBJECTIVE: To evaluate the potential relationship between outcomes in cervical cancer patients based on distance from our Comprehensive Cancer Center (CCC). METHODS: A retrospective cohort study of cervical cancer patients was performed. Abstracted data included: demographics, clinicopathologic variables, treatment, and survival. Analyses both by quartiles and distance <100 and ≥100miles from our institution were performed. Data were analyzed using SAS version 9...
October 6, 2016: Gynecologic Oncology
Amy L Shafrir, Megan S Rice, Mamta Gupta, Kathryn L Terry, Bernard A Rosner, Rulla M Tamimi, Jonathan L Hecht, Shelley S Tworoger
OBJECTIVE: We assessed the association between reproductive and hormonal factors and ovarian cancer incidence characterized by estrogen receptor-α (ERα) and progesterone receptor (PR) status. METHODS: Tissue microarrays were used to assess ERα and PR expression among 197 Nurses' Health Study (NHS), 42 NHSII and 76 New England Case-Control Study (NECC) ovarian cancer cases. NHS/NHSII cases were matched to up to 4 controls (n=954) on diagnosis date and birth year...
October 5, 2016: Gynecologic Oncology
Claudia Marchetti, Gabriella Ferrandina, Gennaro Cormio, Angela Gambino, Sabrina Cecere, Domenica Lorusso, Ugo De Giorgi, Stefano Bogliolo, Anna Fagotti, Serafina Mammoliti, Filomena Narducci, Alice Bergamini, Paolo Scollo, Nicoletta Biglia, Enrico Breda, Stefano Tamberi, Marco Marinaccio, Roberto Angioli, Laura Salerno, Maria Chiara Eusebi, Vera Loizzi, Giovanni Scambia, Pierluigi Benedetti Panici
BACKGROUND: Brain metastases (BM) from epithelial ovarian cancer (EOC) are considered a rare and unfavourable event. There is no consensus regarding the best management of these patients. METHODS: A multicenter retrospective analysis of patients with BM from EOC treated between 1997 and 2014 in 18 institutions of the MITO (Multicenter Italian Trials in Ovarian cancer) group was conducted. Univariate and multivariate analysis were performed. RESULTS: A total of 174 women were identified as having BM from EOC...
October 4, 2016: Gynecologic Oncology
Grace Mishkin, Lori M Minasian, Elise C Kohn, Anne-Michelle Noone, Sarah M Temkin
OBJECTIVES: Enrollment of a representative population to cancer clinical trials ensures scientific reliability and generalizability of results. This study evaluated the similarity of patients enrolled in NCI-supported group gynecologic cancer trials to the incident US population. METHODS: Accrual to NCI-sponsored ovarian, uterine, and cervical cancer treatment trials between 2003 and 2012 were examined. Race, ethnicity, age, and insurance status were compared to the analogous US patient population estimated using adjusted SEER incidence data...
September 30, 2016: Gynecologic Oncology
Ahmed Al-Niaimi, Elizabeth L Dickson, Cassandra Albertin, Jennifer Karnowski, Cassandra Niemi, Ryan Spencer, Mian M K Shahzad, Shitanshu Uppal, Sandeep Saha, Laurel Rice, Amy Mc Nally
OBJECTIVE: To quantify the impact of perioperative β blocker use on survival after primary cytoreductive surgery for epithelial ovarian cancer. METHODS: We conducted a multi-center retrospective study of all women who underwent primary cytoreductive surgery for ovarian cancer (2000-2010). One institution had routinely used perioperative β blockers for patients "at risk" for coronary events. The other institution did not routinely use perioperative β blockers...
September 29, 2016: Gynecologic Oncology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"